{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:49:26Z","timestamp":1788320966942,"version":"build-2803163510"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014764","name":"China International Medical Foundation","doi-asserted-by":"publisher","award":["grant Z-2017-26-1902"],"award-info":[{"award-number":["grant Z-2017-26-1902"]}],"id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Polyethylene glycol loxenatide (PEG-Loxe) is a novel, once-weekly glucagon-like peptide 1 receptor agonist that is approved in doses of 0.1 mg and 0.2 mg for the treatment of type 2 diabetes mellitus (T2DM). However, no clinical trials have been designed to determine the effect of 0.3 mg PEG-Loxe on weight loss in overweight or obese patients with T2DM. This trial aimed to evaluate the short-term effect of 0.3 mg PEG-Loxe, injected subcutaneously once weekly, for weight management in overweight or obese patients with T2DM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This 16-week, open-label, parallel-arm, randomized, metformin-controlled trial was conducted at Shandong Provincial Hospital in Shandong, China. Patients with T2DM, who were overweight or obese (body mass index \u2265 25.0 kg\/m<jats:sup>2<\/jats:sup>) and had been treated with lifestyle interventions or a combination with oral antidiabetic drug monotherapy were randomized (2:1) to receive 0.3 mg PEG-Loxe or 1500 mg metformin. The primary endpoint was a change in body weight from baseline to week 16.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 156 patients were randomized and exposed to treatment. Weight loss was 7.52\u00a0kg (8.37%) with PEG-Loxe and 2.96\u00a0kg (3.00%) with metformin, with a between-group difference of 4.55\u00a0kg (95% CI, 3.43 to 5.67) (<jats:italic>P<\/jats:italic> &amp;lt; 0.001). A significantly higher proportion of patients lost \u22655% (61.5% vs. 25.0%) or 10% (26.9% vs. 5.8%) body weight in the PEG-Loxe group than in the metformin group (<jats:italic>P<\/jats:italic> &amp;lt; 0.01). Additionally, PEG-Loxe resulted in marked improvements in several cardiovascular risk factors compared to metformin, including body mass index, waist circumference, visceral fat area, blood pressure, and lipid profile. PEG-Loxe and metformin displayed almost equal potency for glycemic control. The incidence of adverse events was 46.2% (48\/104) and 44.2% (23\/52) in the PEG-Loxe and metformin groups, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In overweight or obese patients with T2DM, a once-weekly subcutaneous administration of PEG-Loxe for 16 weeks, in addition to lifestyle interventions or oral antidiabetic drug therapy, resulted in significantly greater weight loss compared to metformin. Additional trials are necessary to establish whether these effects can be maintained in the long term.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:uri>www.chictr.org.cn<\/jats:uri>, identifier ChiCTR2200057800.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1106868","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T09:15:13Z","timestamp":1674724513000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial"],"prefix":"10.3389","volume":"14","author":[{"given":"Hongyu","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yale","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.02.035","article-title":"Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients","volume":"126","author":"Ji","year":"2013","journal-title":"Am J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2018.05.004","article-title":"An update on physical health and economic consequences of overweight and obesity","volume":"12","author":"Chu","year":"2018","journal-title":"Diabetes Metab Syndr"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S321756","article-title":"Poor glycemic control and its contributing factors among type 2 diabetes patients at adama hospital medical college in East Ethiopia","volume":"14","author":"Yosef","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.585396","article-title":"Impact of weight gain on outcomes in type 2 diabetes","volume":"27","author":"Ross","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"B5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s11892-014-0473-5","article-title":"Sulfonylureas: a new look at old therapy","volume":"14","author":"Thule","year":"2014","journal-title":"Curr Diabetes Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12761","article-title":"Weight gain in insulin-treated patients by body mass index category at treatment initiation: new evidence from real-world data in patients with type 2 diabetes","volume":"18","author":"Paul","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2017.07.025","article-title":"Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus","volume":"132","author":"Molugulu","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: Established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12397","article-title":"Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients","volume":"9","author":"Chen","year":"2017","journal-title":"J Diabetes"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14163","article-title":"Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 3b trial","volume":"22","author":"Gao","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14198","article-title":"Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial","volume":"23","author":"Shuai","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.386","article-title":"Pharmacokinetics and pharmacodynamics of a polyethylene glycol (PEG)-conjugated GLP-receptor agonist once weekly in Chinese patients with type 2 diabetes","volume":"55","author":"Yang","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabetes Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"B20","doi-asserted-by":"publisher","first-page":"108589","DOI":"10.1016\/j.diabres.2020.108589","article-title":"Mitigation of hypoglycemia during Ramadan using the flash glucose monitoring system following dose adjustment of insulin and sulphonylurea in patients taking multiple glucose-lowering therapies (The PROFAST-IT study)","volume":"172","author":"Elhadd","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"B21","article-title":"Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study","volume":"125","author":"Yuan","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple imputation for nonresponse in surveys","author":"Rubin","year":"1987"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2759","article-title":"Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)","volume":"37","author":"Umpierrez","year":"2014","journal-title":"Diabetes Care"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30267-4","article-title":"Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): A 28 week, multicentre, double-blind, phase 3, randomised controlled trial","volume":"4","author":"Frias","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14020","article-title":"Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study","volume":"22","author":"Del Prato","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1365162","DOI":"10.1155\/2019\/1365162","article-title":"Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity","volume":"2019","author":"Babenko","year":"2019","journal-title":"J Diabetes Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American heart association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.36290\/vnl.2020.014","article-title":"Obesity and cardiovascular disease","volume":"66","author":"Svacina","year":"2020","journal-title":"Vnitr Lek"},{"key":"B30","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/2327-6924.12510","article-title":"Obesity: Risk factors, complications, and strategies for sustainable long-term weight management","volume":"29","author":"Fruh","year":"2017","journal-title":"J Am Assoc Nurse Pract"},{"key":"B31","first-page":"315","article-title":"Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)","volume":"13","author":"Society","year":"2021","journal-title":"Chin J Diabetes Mellitus"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00178","article-title":"GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials","volume":"11","author":"Gilbert","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-016-0490-6","article-title":"Differential effects of glucagon-like peptide-1 receptor agonists on heart rate","volume":"16","author":"Lorenz","year":"2017","journal-title":"Cardiovasc Diabetol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1106868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T09:15:20Z","timestamp":1674724520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1106868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":34,"alternative-id":["10.3389\/fendo.2023.1106868"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1106868","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,26]]},"article-number":"1106868"}}